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This study examined whether antigenic differences among porcine circovirus type 2 (PCV-2)
strains could be detected using monoclonal antibodies (mAbs). A subtractive immunization
protocol was used for the genotype 2 post-weaning multisystemic wasting syndrome
(PMWS)-associated PCV-2 strain Stoon-1010. Sixteen stable hybridomas that produced mAbs
with an immunoperoxidase monolayer assay (IPMA) titre of 1000 or more to Stoon-1010 were
obtained. Staining of recombinant PCV-2 virus-like particles demonstrated that all mAbs were
directed against the PCV-2 capsid protein. Cross-reactivity of mAbs was tested by IPMA and
neutralization assay for genotype 1 strains 48285, 1206, VC2002 and 1147, and genotype 2
strains 1121 and 1103. Eleven mAbs (9C3, 16G12, 21C12, 38C1, 43E10, 55B1, 63H3, 70A7,
94H8, 103H7 and 114C8) recognized all strains in the IPMA and demonstrated neutralization of
Stoon-1010, 48285, 1206 and 1103, but not VC2002, 1147 and 1121. mAbs 31D5, 48B5,
59C6 and 108E8 did not react with genotype 1 strains or had a reduced affinity compared with
genotype 2 strains in the IPMA and neutralization assay. mAb 13H4 reacted in the IPMA with
PMWS-associated strains Stoon-1010, 48285, 1206 and VC2002, and the porcine dermatitis
and nephropathy syndrome-associated strain 1147, but not with reproductive failure-associated
strains 1121 and 1103. mAb 13H4 did not neutralize any of the tested strains. It was
concluded that, despite the high amino acid identity of the capsid protein (¢91%), antigenic
differences at the capsid protein level are present among PCV-2 strains with a different genetic
and clinical background.
INTRODUCTION
Porcine circovirus type 2 (PCV-2) is widespread in
domestic and wild pigs. It belongs to the family
Circoviridae, along with porcine circovirus type 1 (PCV-
1), which was discovered and characterized as a non-
cytopathic contaminant of the continuous porcine kidney
cell line PK-15 (ATCC CCL-33) (Tischer et al., 1974, 1982).
PCV-1 is not regarded as a pathogen for pigs (Tischer et al.,
1986; Allan et al., 1995), whereas PCV-2 is considered as
the crucial pathogen in post-weaning multisystemic
wasting syndrome (PMWS), a multifactorial swine disease
that causes wasting and death in weaned piglets (Harding,
1996; Nayar et al., 1997; Ellis et al., 1998; Allan & Ellis,
2000). Besides wasting, PCV-2 may also cause reproductive
failure (West et al., 1999; Ladekjær-Mikkelsen et al., 2001;
Meehan et al., 2001; Sanchez et al., 2001, 2003; Mateusen
et al., 2004). PCV-2 has also been isolated from pigs with
porcine dermatitis and nephropathy syndrome (PDNS)
and a number of other diseases, but neither PDNS nor
these other diseases have been reproduced experimentally
(Allan et al., 2000; Rosell et al., 2000; Segales et al., 2005,
Wellenberg et al., 2004).
The PCV-2 virion measures approximately 17 nm in
diameter, is non-enveloped and consists of a circular
single-stranded DNA surrounded by an icosahedral capsid
(Allan et al., 1998). The ambisense DNA molecule contains
about 1.77 kb and 11 putative open reading frames (ORFs)
(Hamel et al., 1998). Proteins encoded by three of these
ORFs are considered to play a role in the pathogenesis of
PCV-2 infections. ORF1 encodes the replication-associated
proteins Rep and Rep9 (Mankertz & Hillenbrand, 2001;
Cheung, 2003; Mankertz et al., 2003). Rep and Rep9 are
37.5 and 20.2 kDa, respectively. ORF2 encodes the
The GenBank/EMBL/DDBJ accession numbers of the ORF2
sequences from strains 1206, VC2002-k2 and VC2002-k39 deter-
mined in this study are EF990644, EF990645 and EF990646,
respectively.
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27.8 kDa capsid protein (Hamel et al., 1998; Meehan et al.,
1998; Morozov et al., 1998; Mankertz et al., 2000;
Nawagitgul et al., 2000). The ORF2 protein is the only
structural protein. The ORF3 protein has a molecular mass
of 11.8 kDa and has recently been associated with
apoptosis in vitro and with viral pathogenesis in mice
(Liu et al., 2005, 2006).
Meerts et al. (2005a) demonstrated biological differences
among different PCV-2 strains in vitro. Replication kinetics
of PMWS- and PDNS-associated PCV-2 strains were
significantly different from reproductive failure-associated
PCV-2 strains. Recently, it was demonstrated that the
virulence of a PCV-2 isolate originating from a PMWS-
affected animal differed significantly from an isolate
recovered from a subclinically infected animal. Important
differences in serological profile, virus replication and
severity of lesions were shown after experimental inocu-
lation of specific-pathogen-free (SPF) pigs (Opriessnig
et al., 2006).
Among various strains of PCV-2, the identity at the
nucleotide level of the Rep protein and the capsid protein is
97–100% and 91–100%, respectively. At protein level,
identity is 97–100% for Rep and 89–100% for the capsid
protein (Larochelle et al., 2002). Several studies have
suggested that genetic differences in PCV-2 are associated
with the geographical region from which the isolates
originated (Fenaux et al., 2000; Hamel et al., 2000;
Mankertz et al., 2000; Kim & Lyoo, 2002) and a recently
proposed classification system (Olvera et al., 2007) divides
PCV-2 into two genotypes (1 and 2) and eight clusters
(1A–1C and 2A–2E). Although several antigenic domains
have been discovered on the capsid protein (Mahe´ et al.,
2000; Lekcharoensuk et al., 2004; Olvera et al., 2007), no
association has been established so far between the
sequence of the capsid and the pathogenicity of a PCV-2
strain (Fenaux et al., 2000; Meehan et al., 2001; Larochelle
et al., 2002; Pogranichniy et al., 2002; de Boisse´son et al.,
2004; Grierson et al., 2004). Until now, mouse monoclonal
antibodies (mAbs) directed against PCV-2 have not shown
major differences in reactivity to different PCV-2 strains
(Allan et al., 1999; McNeilly et al., 2001).
In this study, mAbs to PCV-2 were produced, characterized
and used to identify antigenic differences among PCV-2
strains with a different genotype and originating from
different clinical presentations.
METHODS
Viruses. Seven different PK-15-adapted PCV-2 strains were used in
this study. Their origin and genotype (Cheung et al., 2007; Olvera
et al., 2007) are shown in Table 1. The replication kinetics of
these strains have been documented previously (Meerts et al., 2005a).
PCV-1 originated from the persistently infected PK-15 cell line ATCC
CCL-33 (Tischer et al., 1974, 1982). All PCV-2 strains used were
passaged 11–17 times, except for strain 1121, which was passaged
30 times.
Recombinant PCV-2 virus-like particles. PCV-2 virus-like parti-
cles (VLPs) were obtained by infecting Sf9 insect cells with a
baculovirus recombinant P054 expressing the ORF2 of PCV-2 strain
Stoon-1010. Purification of VLPs was performed in a caesium
chloride gradient as described by Nawagitgul et al. (2000).
Cells. PCV-negative PK-15 cells and the persistently PCV-1-infected
PK-15 cell line ATCC CCL-33 were grown in minimal essential
medium (MEM) containing Earle’s salts (Gibco), supplemented with
5 or 10% fetal bovine serum (FBS), 0.3 mg glutamine ml21, 100
U penicillin ml21, 0.1 mg streptomycin ml21 and 0.1 mg kanamycin
ml21. Cell cultures were maintained at 37 uC in the presence of 5%
CO2.
Mouse immunization. Before immunization, mice were made
immunotolerant to PK-15 cells as described by Matthew &
Sandrock (1987). Four 6-week-old female BALB/c mice were injected
intraperitoneally (i.p.) with 1.56107 PCV-negative PK-15 cells in
300 ml PBS. After 10 min, 24 and 48 h, cyclophosphamide (Sigma)
was injected i.p. at a dose of 100 mg (kg body weight)21 in a total
volume of 500 ml PBS. After 3 and 6 weeks, injections with PK-15
cells and cyclophosphamide were repeated. Two weeks after the last
treatment, 2.256107 Stoon-1010-inoculated PK-15 cells were injected
i.p. in a volume of 300 ml PBS mixed with an equal amount of
complete Freund’s adjuvant (Sigma). At this time point and 2 weeks
later, serum was collected from mice. Three weeks after the
inoculation with PCV-2, one mouse received an i.p. injection
with 4.56107 Stoon-1010-inoculated PK-15 cells diluted in 600 ml
PBS. Euthanasia was performed 4 days later and the spleen was
collected.
Production and screening of hybridomas. Hybridoma cells were
produced by fusion of spleen cells with SP 2/0 myeloma cells as
described by Galfre & Milstein (1981). The resulting hybridoma cells
were maintained in RPMI 1640 (Gibco) supplemented with 10% FBS.
PCV-2-specific mAbs in supernatant fluids were demonstrated on
Table 1. Origins of the PCV-2 strains used in this study
Strain Clinical origin Genotype Geographical origin Reference
Stoon-1010 PMWS-affected piglet 2 Canada Meehan et al. (1998)
48285 PMWS-affected piglet 1 France Meehan et al. (1998)
1206 PMWS-affected piglet 1 Belgium Meerts et al. (2005a)
VC2002 PMWS-affected piglet 1 Belgium Meerts et al. (2004)
1147 PDNS-affected piglet 1 UK Meehan et al. (2001)
1121 Aborted fetuses 2 Canada Meehan et al. (2001)
1103 Aborted fetuses 2 Canada Meehan et al. (2001)
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PCV-negative and Stoon-1010-inoculated PK-15 cells by an immuno-
peroxidase monolayer assay (IPMA) adapted from Labarque et al.
(2000). After incubation with undiluted supernatant fluids for 1 h at
37 uC, cells were washed twice with PBS. Subsequently, a 1 : 500
dilution of horseradish peroxidase-labelled goat anti-mouse
polyclonal antibodies (pAbs) (Dako) in PBS was added for 1 h at
37 uC. After washing twice in PBS, substrate solution was added and
cell cultures were analysed by light microscopy (Olympus Optical
Co.). Selected hybridoma cultures were cloned by limiting dilution.
Determination of mAb class. The isotype of the produced mAbs
was determined using a peroxidase-based commercial mouse mAb
identification kit (Zymed). This test identifies the IgG1, IgG2a, IgG2b,
IgG3, IgA and IgM isotype classes and the k and l type of the light
chain using monospecific rabbit pAbs. Supernatant fluids of anti-PRV
mAbs 13D12 (IgG1) and 1C11 (IgG2a) (Nauwynck & Pensaert, 1995)
and anti-Escherichia coli mAb E7G3 (IgG3) (Tiels et al., 2007) were
used as positive controls.
Indirect immunofluorescence staining of recombinant PCV-2
VLPs. The VLP staining technique was adapted from Misinzo et al.
(2005). Briefly, purified VLPs were diluted 1 : 100 in PBS, smeared
onto microscope slides, air dried and fixed with 3% (w/v)
paraformaldehyde in PBS for 10 min at room temperature. Fixed
VLPs were incubated with undiluted hybridoma supernatants for 1 h
at 37 uC, followed by incubation with a 1 : 500 dilution of fluorescein
isothiocyanate-labelled goat anti-mouse pAbs (Molecular Probes)
containing 10% PCV-2-negative goat serum for 1 h at 37 uC. mAb
F217 (McNeilly et al., 2001) diluted 1 : 50 in PBS was used as a
positive control. mAbs 13D12 and 1C11 were included as negative
controls. A Leica DM/RBE fluorescence microscope (Leica
Microsystems) was used for visualization.
Western blot analysis. Stoon-1010-inoculated and mock-inocu-
lated PCV-negative PK-15 cells were harvested by scraping. Cells were
pelleted by centrifugation at 15 700 g for 20 min at 4 uC and
subsequently lysed for 1 h at 37 uC in TNE [50 mM Tris/HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA] containing 1% NP-40
(Roche), protease inhibitors (Complete; Roche) and 0.5% SDS.
Cells were centrifuged at 15 700 g for 10 min at 4 uC and resuspended
in a non-reducing Laemmli buffer. This mixture was boiled for 5 min
and stored at 220 uC until use. Proteins were separated by standard
SDS-PAGE (Laemmli, 1970) and transferred to a PVDF membrane
(Amersham Biosciences). This membrane was then incubated for 1 h
at room temperature in PBS containing 0.1% Tween 20 (PBS-
Tween), supplemented with 5% BSA (Sigma). After washing in PBS-
Tween, membranes were incubated overnight at 4 uC with a 1 : 5
dilution of the mAbs in PBS-Tween. mAb F190 (McNeilly et al., 2001)
and biotinylated purified porcine pAbs, originating from a PCV-2-
negative SPF pig inoculated with strain 1121 (Pensaert et al., 2004;
Meerts et al., 2005a), were used as positive controls. mAbs 13D12 and
1C11 were included as negative controls. Next, a 1 : 300 dilution of
biotinylated sheep anti-mouse pAbs and a 1 : 300 solution of a
streptavidin–biotinylated horseradish peroxidase complex
(Amersham Biosciences) was applied. Membranes were washed twice
with PBS-Tween between incubations. Antigen–antibody complexes
were visualized using an enhanced chemiluminescence assay
(Amersham Biosciences).
Reactivity of mAbs to different PCV-2 strains. PCV-2 strains
Stoon-1010, 48285, 1206, VC2002, 1147, 1121 and 1103 were used to
prepare 96-well IPMA plates as described by Labarque et al. (2000).
PCV-negative PK-15 cells and the persistently PCV-1-infected PK-15
cell line were used for control IPMA plates. The staining procedure was
similar to the IPMA technique described above. Tenfold dilutions of
hybridoma supernatants were prepared in PBS and used as primary
antibodies. IPMA antibody titres of a hybridoma supernatant were
expressed as the reciprocal of the last dilution that resulted in a positive
reaction. These assays were performed three times for each strain.
Sensitive neutralization assays. In order to detect the neutralizing
activity of the mAbs, a sensitive neutralization assay was adapted from
the method of Meerts et al. (2005b). Briefly, 104.3 TCID50 PCV-2 in a
volume of 200 ml was incubated for 1 h at 37 uC with 200 ml
undiluted hybridoma supernatant. After incubation, this mixture was
added to semi-confluent monolayers of PCV-negative PK-15 cells in
four wells of a 96-well plate. After 1 h at 37 uC, cell cultures were
washed twice in MEM and fresh medium was added. Cell cultures
were fixed 36 h later. At this time point, the first replication cycle of
PCV-2 was completed (Meerts et al., 2005a). PCV-2-infected PK-15
cells were stained by an IPMA using porcine PCV-2-specific pAbs,
originating from a Stoon-1010-inoculated gnotobiotic pig. The
number of infected cells per well was determined by light microscopy.
The neutralizing activity of a hybridoma supernatant was expressed as
the percentage reduction in the number of infected cells in
comparison with medium. Assays were performed with all seven
strains. Anti-PCV-2 mAb F190 was used as a positive control. mAbs
13D12 and 1C11 were used as negative controls. A mAb was
considered as neutralizing when its mean neutralizing activity was
higher than the mean neutralizing activity+SD of the negative
controls. Sensitive neutralization experiments were performed three
times for each strain.
Sequencing of ORF2 from strains 1206 and VC2002. The Belgian
PCV-2 strains 1206 and VC2002 were purified by ultracentrifugation
at 180 000 g for 3 h through a 30% sucrose gradient as described by
Delputte et al. (2002). A set of PCR primers was designed based on
alignment of the genome sequences of strains Stoon-1010, 48285,
1147, 1121 and 1103. The primer set PCV-2-FW (59-AGCGCAC-
TTCTTTCGTTTTCAG-39) and PCV-2-REV (59-GAATGCGGCCG-
CTTATCACTTCGTAATGGTTTTTATTATTCA-39) amplified the
complete ORF2. Two internal oligonucleotides were synthesized:
CV1 (59-GGGCTGTGGCCTTTGKTAC-39) and CV2 (59-TGTR-
GACCACGTAGGCCTCG-39). These internal oligonucleotides were
as described by Fenaux et al. (2000) with minor modifications, and
were used for sequencing. A 1 : 200 fraction of proteinase K-treated
ultrapurified PCV-2 was used as template in PCRs using Platinum Pfx
DNA polymerase (Invitrogen) at an annealing temperature of 60 uC
and using the cycling conditions described by the manufacturer. PCR
products (~800 bp) were treated with exonuclease I and antarctic
phosphatase (New England Biolabs) and used directly for cycle
sequencing with a Big Dye Terminator Cycle Sequencing kit v1.1
(Applied Biosystems) and PCV-2 primers. Cycle sequencing reaction
products were purified using ethanol precipitation and separated on an
ABI Genetic Analyzer 310 (Applied Biosystems). Additionally, PCR
products (~800 bp) were gel purified using a QIAquick gel extraction
kit (Qiagen) and cloned in pBluescript II SK(+) cut with EcoRV and
treated with antarctic phosphatase. Clones containing the PCV-2 ORF2
were sequenced using T7 and T3 primers as described above. The
sequences were analysed and compiled using Align, LAlign, CLUSTAL W
and Sixframe in the Biology Workbench (http://workbench.sdsc.edu)
and Align2sequences, BLASTN and BLASTP at www.ncbi.nlm.nih.gov.
Phylogenetic relationships among sequences were analysed as described
by Tripathi & Sowdhamini (2006). Briefly, phylogenetic trees were
derived from multiple sequence alignments with PHYLIP v3.67.
Bootstrapping was performed 100 times using SEQBOOT. Pairwise
distances between genomic sequences and protein sequences were
determined with DNADIST and PROTDIST, respectively. Neighbour-
joining (NJ) trees were calculated with neighbour and maximum-
likelihood (ML) trees with DNAML and ProML. Majority rule consensus
trees were obtained with CONSENSE and visualized with DRAWGRAM.
The ORF2 sequences (702 nt, from ATG to the stop codon) from
strains 1206, VC2002-k2 and VC2002-k39 have been deposited in
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GenBank under accession numbers EF990644, EF990645 and
EF990646, respectively.
RESULTS
Mouse immunization
Prior to immunization, four BALB/c mice were made
immunotolerant to PK-15 cells by repeated injection of
PCV-negative PK-15 cells and cyclophosphamide. After
this treatment, no or little reaction to PK-15 cells was
observed in IPMAs. All serum samples taken before
immunization were negative for anti-PCV-2 antibodies as
determined by IPMA. Two weeks after the first immun-
ization, all mice had anti-Stoon-1010 antibody titres of
between 2560 and 40 960. One mouse with an IPMA titre
of 10 240 and without reaction to PK-15 cells was selected.
It received a boost injection 1 week later and its spleen was
used for the production of hybridomas.
Production and screening of hybridomas
Forty-four hybridomas that produced mAbs against PCV-
2-infected PK-15 cells were frozen. Cloning by limiting
dilution resulted in 16 stable hybridomas that produced
mAbs with an IPMA titre of 1000 or more to Stoon-1010.
Determination of mAb class
A commercial identification kit was used to determine the
isotypes of the mAbs. The results are presented in Table 2.
Six hybridomas produced IgG1 mAbs and eight hybrido-
mas produced IgG2a mAbs. mAb 21C12 had an IgG3
isotype. The isotype of mAb 48B5 could not be determined.
All mAbs, including mAb 48B5, had a light chain of the k
type.
Indirect immunofluorescence staining of
recombinant PCV-2 VLPs
The reactivity of the mAbs to VLPs was tested by
performing indirect immunofluorescence staining of
VLPs smeared onto glass slides. All 16 mAbs reacted with
the VLPs, indicating that the mAbs were directed against
the PCV-2 capsid protein. No staining was observed with
irrelevant mAbs.
Western blot analysis
The reactivity of the mAbs to Stoon-1010-inoculated PK-
15 cells was determined in a Western blot assay. mAbs
31D5, 38C1 and 108E8 gave a strong and specific reaction
with a protein of approximately 28 kDa (Fig. 1). For mAb
21C12, a faint but specific band was observed at 28 kDa
Table 2. Isotype and IPMA antibody titres of hybridoma supernatants
IPMA antibody titres of a hybridoma supernatant were expressed as the reciprocal of the last dilution that resulted in a positive reaction.
mAb Isotype IPMA antibody titres
1010 48285 1206 VC2002 1147 1121 1103 PCV-1
PMWS PMWS PMWS PMWS PDNS Abortion Abortion
Genotype 2 Genotype 1 Genotype 1 Genotype 1 Genotype 1 Genotype 2 Genotype 2
9C3 IgG1 10 000 10 000 10 000 10 000 10 000 10 000 10 000 Negative
13H4 IgG2a 1 000 1 000 1 000 100 100 Negative Negative Negative
16G12 IgG2a 10 000 10 000 10 000 10 000 10 000 10 000 10 000 Negative
21C12 IgG3 1 000 1 000 1 000 1 000 1 000 1 000 1 000 Negative
31D5 IgG1 10 000 Negative Negative/1 000* Negative Negative 10 000 10 000 Negative
38C1 IgG1 100 000 10 000 100 000 100 000 100 000 100 000 100 000 Negative
43E10 IgG1 1 000 1 000 1 000 1 000 1 000 1 000 1 000 Negative
48B5 No reaction 1 000 Negative Negative/100* Negative Negative 1 000 100 Negative
55B1 IgG2a 10 000 1 000 10 000 10 000 10 000 10 000 10 000 Negative
59C6 IgG2a 10 000 10 100/10 000* 100 100 10 000 10 000 Negative
63H3 IgG2a 10 000 1 000 1 000 1 000 10 000 10 000 10 000 Negative
70A7 IgG2a 10 000 1 000 1 000 10 000 10 000 10 000 1 000 Negative
94H8 IgG2a 10 000 10 000 10 000 10 000 10 000 10 000 10 000 Negative
103H7 IgG2a 10 000 1 000 10 000 10 000 10 000 10 000 10 000 Negative
108E8 IgG1 1 000 10 Negative/1 000* 1 1 1 000 1 000 Negative
114C8 IgG1 1 000 1 000 1 000 1 000 1 000 1 000 1 000 Negative
*mAbs 31D5, 48B5, 59C6 and 108E8 stained two different populations of infected cells in strain 1206. IPMA titres for the first population (~99% of
the infected cells, on the left of the slash) were comparable to those of the genotype 1 strains 48285, VC2002 and 1147. IPMA titres for the second
population (~1% of the infected cells, on the right of the slash) were comparable to those of the genotype 2 strains 1010, 1121 and 1103. These
populations were determined by counting the number of infected cells per well after staining with different dilutions of the mAbs.
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(not shown). None of the other mAbs showed reactivity in
the Western blot assay.
Reactivity of mAbs to different PCV-2 strains
An IPMA was used to examine the reactivity of hybridoma
supernatants to seven different PCV-2 strains (Table 2).
Eleven out of 16 hybridomas stained all seven strains with a
maximum tenfold variation in titres among the strains
(9C3, 16G12, 21C12, 38C1, 43E10, 55B1, 63H3, 70A7,
94H8, 103H7 and 114C8). mAbs 31D5, 48B5, 59C6 and
108E8 did not react with the genotype 1 strains 48285,
VC2002 and 1147, or they had IPMA antibody titres to
these strains that were at least 100 times lower than for the
genotype 2 strains Stoon-1010, 1121 and 1103. These four
mAbs stained two different populations of infected cells in
strain 1206. IPMA antibody titres for the first population
(~99% of the infected cells) were comparable to those of
the other genotype 1 strains. IPMA antibody titres for the
second population (~1% of the infected cells) were
comparable to those of the genotype 2 strains. These
populations were determined by counting the number of
infected cells per well after staining with different dilutions
of the mAbs. mAb 13H4 stained all four PMWS-associated
strains (Stoon-1010, 48285, 1206 and VC2002) and the
single PDNS-associated strain (1147), but did not react
with the two reproductive failure-associated strains (1121
and 1103). None of the 16 mAbs reacted with PCV-1 or
with PK-15 cells.
Sensitive neutralization assays
A sensitive neutralization assay was used to determine the
neutralizing activity of hybridoma supernatants. Table 3
shows the percentage neutralization±SD of the different
mAbs. The neutralizing activities of mAbs 13D12 and 1C11
were 7±19 and 21±14%, respectively. As the mean
neutralizing activity of mAb 13D12+SD was 7+19526%,
Fig. 1. Western blot analysis of PCV-2 Stoon-1010-inoculated
and mock-inoculated PK-15 cells. Odd numbers represent Stoon-
1010-inoculated cell lysates, whilst even numbers show mock-
inoculated cell lysates. Lanes: 1 and 2, mAb F190 (positive
control); 3 and 4, mAb 31D5; 5 and 6, mAb 38C1; 7 and 8, mAb
108E8. All four mAbs reacted specifically with a 28 kDa protein
(arrowheads).
Table 3. Neutralizing activity of hybridoma supernatants
The neutralizing activity of a hybridoma supernatant was expressed as the percentage reduction in the number of infected cells in comparison with
medium. A mean neutralizing activity of 30% or more was considered to be neutralization (indicated in bold).
mAb Neutralization (±SD) (%)
1010 48285 1206 VC2002 1147 1121 1103
PMWS PMWS PMWS PMWS PDNS Abortion Abortion
Genotype 2 Genotype 1 Genotype 1 Genotype 1 Genotype 1 Genotype 2 Genotype 2
9C3 94±3 92±5 54±10 1±13 34±20 11±12 54±16
13H4 23±14 8±15 10±14 12±12 24±15 7±11 6±16
16G12 91±3 90±6 41±14 6±18 19±15 24±9 26±11
21C12 94±1 82±8 44±14 32±16 0±19 212±18 56±21
31D5 92±2 11±13 6±9 24±8 6±20 3±12 54±20
38C1 95±1 94±2 42±17 20±10 30±20 213±13 61±16
43E10 79±2 89±2 38±18 2±4 22±20 6±2 56±12
48B5 98±0 19±6 16±5 25±3 27±7 23±22 49±13
55B1 84±2 94±2 55±16 22±3 25±12 6±4 32±15
59C6 72±3 30±9 17±13 4±9 4±10 6±16 28±20
63H3 72±4 77±3 30±16 0±5 10±8 214±18 50±17
70A7 88±2 89±2 57±17 10±1 21±12 29±10 39±16
94H8 62±14 82±4 49±14 6±5 16±12 2±2 56±8
103H7 51±6 62±9 32±12 5±12 8±22 3±14 55±19
108E8 88±2 35±11 9±9 8±3 2±9 26±14 67±5
114C8 71±4 74±7 39±23 14±4 20±9 210±17 51±5
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a mAb was arbitrarily considered as neutralizing when its
mean neutralizing activity was higher than 30%. The 11
mAbs (9C3, 16G12, 21C12, 38C1, 43E10, 55B1, 63H3,
70A7, 94H8, 103H7 and 114C8) that reacted equally with
all seven PCV-2 strains in the IPMA demonstrated
neutralization of Stoon-1010 (up to 95%), 48285 (up to
94%), 1206 (up to 57%) and 1103 (up to 61%). The four
mAbs (31D5, 48B5, 59C6 and 108E8) that had a higher
affinity for genotype 2 strains than for genotype 1 strains in
the IPMA demonstrated neutralization of the genotype 2
strains Stoon-1010 (up to 98%) and 1103 (up to 67%).
For these four mAbs, neutralization of genotype 1 strains
48285 and 1206 was absent or very low (up to 35%). mAb
13H4 did not neutralize any of the seven tested strains.
Only one mAb (21C12) demonstrated some neutralization
(32%) of strain VC2002 and only two mAbs (9C3 and
38C1) demonstrated some neutralization (34 and 30%,
respectively) of strain 1147. None of the 16 mAbs
neutralized strain 1121.
Sequencing of ORF2 from strains 1206 and
VC2002
The ORF2 of the Belgian PMWS-associated PCV-2 strains
1206 and VC2002 was amplified by PCR and sequenced.
Strain 1206 contained an ORF2 of 702 bp (starting from
ATG and including the stop codon) encoding a 233 aa
protein. Sequencing of the VC2002 ORF2 PCR product
resulted in a sequence containing ambiguities at different
positions. Therefore, the VC2002 PCR fragment was cloned
in pBluescript II SK(+) and 12 clones were sequenced.
Clone VC2002-k39 contained an ORF of 702 bp (starting
from ATG and including the stop codon) encoding a
protein of 233 aa. Ten other VC2002 clones were almost
100% identical at the nucleotide level with clone k39 with
between 1 and 3 nt differences. Clone VC2002-k2 showed
94% identity with k39 at the nucleotide and amino acid
levels and 96–99% amino acid identity with strains from
China (e.g. NCBI protein database accession nos
AAP44186, AAU87508 and AAT97651), The Netherlands
(accession no. AAS65982; Grierson et al., 2004) and a
strain isolated from wild boars in Germany (accession no.
AAU13781; Knell et al., 2005). Capsid protein similarity
among the seven different strains used in this study was
determined using pairwise alignments and CLUSTAL W
(Fig. 2). The ORF2 amino acid identities of the strains
used in this study is shown in Table 4. Fig. 3 shows a
phylogenetic tree of the ORF2 protein based on the NJ
method with the percentage confidence shown on each
branch. This tree was constructed with ORF2 protein
sequences from this study and sequences chosen from the
different clusters from Olvera et al. (2007). The latter
sequences are shown in Table 5. Genotype 1 strains 48285,
1206, VC2002-k39 and 1147 were assigned to cluster 1A/
1B, VC2002-k2 to cluster 1C and genotype 2 strains Stoon-
1010, 1121 and 1103 to cluster 2E. The same strain
classification was obtained by using the ML method and
with ORF2 DNA sequences.
Fig. 2. ORF2 amino acid alignment of the PCV-2 strains used in this study. GenBank accession numbers are: EF990644
(1206), AJ293869 (1147), AF055394 (48285), EF990646 (VC2002-k39), EF990645 (VC2002-k2), AJ293868 (1121),
AJ293867 (1103) and AF055392 (Stoon-1010). An asterisk indicates a single, fully conserved residue, a colon indicates
conservation of strong groups, and a dot represents conservation of weak groups; spaces indicate no consensus (amino acids
shown in bold).
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DISCUSSION
This is the first study to demonstrate antigenic diversity
among PCV-2 strains. This was established by the
production and characterization of mAbs directed to the
PCV-2 capsid protein. The cross-reactivity of the mAbs to
seven different PCV-2 strains with a different genotype
and originating from various clinical conditions was
determined.
Eleven mAbs (9C3, 16G12, 21C12, 38C1, 43E10, 55B1,
63H3, 70A7, 94H8, 103H7 and 114C8) reacted equally with
the seven PCV-2 strains used in the IPMA. Four other
mAbs (31D5, 48B5, 59C6 and 108E8) were able to
differentiate the genotype 1 strains 48285, 1206, VC2002
and 1147 from the genotype 2 strains Stoon-1010, 1121
and 1103 by IPMA, as they did not react with genotype
1 strains or had a reduced affinity compared with genotype
2 strains. The IPMA results of the latter four mAbs were
also reflected in the neutralization assays. Until now, mAbs
have not allowed differentiation of PCV-2 strains (Allan
et al., 1999; McNeilly et al., 2001). mAbs 31D5, 48B5, 59C6
and 108E8 also did not react with or had a reduced affinity
for tissue sections originating from the Belgian PMWS-
affected pig from which the VC2002 strain was isolated.
This was demonstrated by immunofluorescence staining
and suggests that the results obtained by IPMA for mAbs
31D5, 48B5, 59C6 and 108E8 were not a consequence of
PCV-2 cell culture adaptation (data not shown).
Using the IPMA, mAbs 31D5, 48B5, 59C6 and 108E8
stained two different populations of infected cells in strain
1206. This suggests that strain 1206 consists of two viral
subpopulations, where 99% of the virus behaves as a
genotype 1 strain and 1% of the virus behaves as a
genotype 2 strain. No signs of the existence of subpopula-
tions were detected by sequencing of strain 1206. This may
be explained by the fact that the putative genotype 2
subpopulation was present at a very low level (1%).
Sequencing of the VC2002 strain did reveal the existence of
two PCV-2 subpopulations in the virus stock. After
cloning, two distinct sequences were derived from strain
VC2002. Phylogenetic analysis assigned clone VC2002-k39
to cluster 1A/1B and demonstrated clustering of clone
VC2002-k2 with strains from China, The Netherlands
(Grierson et al., 2004) and a strain isolated from German
wild boars (Knell et al., 2005), which documents the
putative epidemiological link between PCV-2 infections in
Table 4. ORF2 amino acid identity within PCV-2 strains used in this study
The percentage amino acid identities given are the result of pairwise alignments of the ORF2 proteins. Percentage identities between the genotype 1
strains (except VC2002-k2) are shown in bold; percentage identities between the genotype 2 strains are shown in bold and italics; percentage
identities between the VC2002-k2 strain and other strains are underlined.
Strain 1206 1147 48285 VC2002-k39 1121 1103 1010 VC2002-k2
1206 100 98 98 98 92 91 93 93
1147 100 98 98 92 91 92 93
48285 100 98 93 92 93 94
VC2002-k39 100 93 93 93 94
1121 100 98 97 91
1103 100 97 91
1010 100 92
VC2002-k2 100
Fig. 3. Unrooted phylogenetic tree constructed using the NJ
method. The percentage confidence is indicated on the branches.
This tree was based on the ORF2 protein sequences of the PCV-2
strains that were used in the present study (strain names in
parentheses), one PCV-1 sequence (outgroup) and 20 PCV-2
sequences that were obtained from Olvera et al. (2007). These
sequences are listed in Table 5. *, No NCBI protein accession
number was available for the ORF2 protein, so the GenBank
nucleotide sequence was used.
Antigenic differences among PCV-2 strains
http://vir.sgmjournals.org 183
domestic and wild pigs (Csa´gola et al., 2006). The
identification of two different PCV-2 sequences in one
animal has been reported previously (de Boisse´son et al.,
2004; Opriessnig et al., 2006; Cheung et al., 2007), but the
role of multiple PCV-2 infections in the pathogenesis of
PCV-2-associated diseases is not clear.
Using protein sequences (NJ and ML methods), we were
not able to differentiate between clusters 1A and 1B, and
not all sequences that were previously classified as 1C
(Olvera et al., 2007) were found in the 1C cluster. Using the
corresponding DNA sequences (NJ and ML methods), the
same topology was obtained as by Olvera et al. (2007), with
the only difference being that clusters 1A and 1B could not
be differentiated in the present study (data not shown). We
assume that these differences are a consequence of the
reduced number of sequences used.
Putative amino acid substitutions that discriminate the
genotype 1 strains 48285, 1206, VC2002-k39 and 1147
from the genotype 2 strains Stoon-1010, 1121 and 1103 are
located at positions 63, 88, 89 and 206. At position 63, a
threonine was substituted for a lysine or an arginine. At
position 88, a lysine was replaced by a proline, and at
position 89, an isoleucine was replaced by an arginine.
These three substitutions all involve the basic amino acids
lysine and arginine. Due to the differences in size, charge
and hydrophobicity between lysine/arginine and threonine,
proline and isoleucine, this may have major consequences
on the secondary and tertiary structure of the PCV-2
capsid protein. The same applies to position 206, where a
lysine was replaced by an isoleucine. Linear antigenic
determinants of the PCV-2 ORF2 protein, as determined
by PEPSCAN, are located at positions 65–87, 113–139, 169–
183 and 193–207 (Mahe´ et al., 2000). Positions 63, 88 and
89, where non-conserved mutations were found in the
present study, are located at the outer borders of linear
epitope 65–87, whereas position 206, where another non-
conserved mutation was found, is located at the inner
border of linear epitope 193–207. Therefore, we speculate
that the amino acid substitutions that involve basic amino
acids at positions 63, 88, 89 and 206 might be responsible
for the fact that mAbs 31D5, 48B5, 59C6 and 108E8 did not
react with the genotype 1 strains or that they had a reduced
affinity for these strains in the IPMA and neutralization
assay.
This study also demonstrated that mAb 13H4 did not react
specifically with the reproductive failure-associated strains
1121 and 1103 in the IPMA. Strains 1121 and 1103 have a
proline at position 131 instead of a threonine (T131P) and
an arginine instead of a glycine at position 191 (G191R).
Proline is known to be a helix breaker and glycine has a
great conformational flexibility. Apart from the changes in
the primary structure of the protein, T131P and G191R
may have important consequences on the secondary and
tertiary structure of the protein. Position 131 is located
within, and position 191 is located at the outer border of,
an antigenic domain (Mahe´ et al., 2000). Therefore, the
substitutions at positions 131 and 191 might be involved in
the absence of reaction of mAb 13H4 with strains 1121 and
1103. Previously, it was demonstrated by Meerts et al.
(2005a) that the production of infectious virus in PK-15
cells is more efficient for Stoon-1010 than for strain 1121.
Table 5. Name, phylogenetic cluster (according to Olvera et al., 2007) and origin of the ORF2 sequences used in Fig. 3
NCBI protein
accession no.
GenBank accession
no.
Strain Cluster Clinical
origin
Geographical
origin
Reference
– U49186 pPCV-PSTI PCV-1 PK-15 cell line UK Meehan et al. (1997)
AAT97649 AY686764 ZJ 1A Unknown China
AAR03721 AY424404 AUT4 1A Unknown Austria
AAU87510 AY682992 CHST 1B Unknown China
AAS66195 AY556475 GX 1B PMWS China
AAK60463 AY035820 – 1C PMWS China Song et al. (2007)
AAS66199 AY556477 HuNan 1C PMWS China
AAP44186 AY291317 HB 1C PMWS China
AAU87508 AY682991 CHL 1C Unknown China
AAT97651 AY686765 JXIII 1C Unknown China
AAS65982 AY484410 Nl-Control-4 1C Subclinical Netherlands Grierson et al. (2004)
AAU13781 AY713470 Wild boar 1C Subclinical Germany Knell et al. (2005)
BAB69440 AB072302 No. 26 2A PMWS Japan
AAO23146 AY180396 Pingtung-4 2B Unknown Taiwan
AAN62766 AY146991 Pingtung-1 2B Unknown Taiwan
AAQ94089 AY256455 212 2C PDNS Hungary Da´n et al. (2003)
AAF35299 AF201308 SPA1 2C PMWS Spain Mankertz et al. (2000)
AAQ94095 AY256458 326 2D PMWS Hungary Da´n et al. (2003)
AAF35295 AF201306 GER2 2D PMWS Germany Mankertz et al. (2000)
AAM21849 AY094619 688 2E PMWS Canada Cheung (2003)
AAF87229 AF264039 26607 2E PMWS USA Fenaux et al. (2000)
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Fenaux et al. (2004) demonstrated that PCV-2 that was
passaged 120 times in PK-15 cells (VP120) replicated more
efficiently in PK-15 cells than wild-type virus that had been
passaged only once (VP1). Differences between VP1 and
VP120 were a mutation from proline to alanine at position
110 (P110A) and a mutation from arginine to serine at
position 191 (R191S). This may suggest that basic amino
acid residues at position 191 influence not only mAb
reactivity, but also the production of infectious virus.
Recently, it was demonstrated that PMWS-affected animals
are not able to produce neutralizing antibodies, whereas
their ability to produce non-neutralizing antibodies
remains unaffected (Meerts et al., 2005b, 2006; Fort et al.,
2007). In these studies, it was suggested that PMWS-
affected animals mount an immune response to non-
neutralizing epitopes but not to neutralizing epitopes. In
the present study, none of the tested mAbs was able to
neutralize all seven PCV-2 strains, suggesting that a
universal PCV-2 neutralizing epitope does not exist.
Neutralization was observed for Stoon-1010, 48285, 1206
and 1103, but not VC2002, 1147 and 1121. No discrim-
inative amino acid motifs that could explain these results
were detected. The mAbs that neutralized Stoon-1010,
48285, 1206 and 1103 did not differentiate these strains
from VC2002, 1147 and 1121 in the IPMA, indicating that
these two different groups of PCV-2 strains have different
neutralizing epitopes, and suggesting that these two
different groups of PCV-2 strains use different entry
pathways in PK-15 cells. Recently, the glycosaminoglycans
heparan sulfate and chondroitin sulfate B have both been
described as attachment receptors for PCV-2 (Misinzo
et al., 2006). Protein binding to these two attachment
receptors is restricted to the basic amino acids lysine and
arginine (Esko, 1999), suggesting a crucial role of basic
amino acid residues in the entry of PCV-2 into the host
cell. The positive amino acid charges of lysine and arginine
interact three-dimensionally with negatively charged gly-
cosaminoglycan sulfates and carboxylates (Esko, 1999),
which indicates that three-dimensional conformation plays
a crucial role in interactions between the PCV-2 capsid
protein and its receptors.
Until now, it was assumed that no distinct antigenic
variation existed among PCV-2 isolates. In this study, we
have clearly demonstrated the existence of major antigenic
differences among the capsid proteins of PCV-2 strains
with a different genotype and isolated from different
clinical presentations.
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